Institutional Capital Returns as This Microcap Biotech Locks In Fresh Funding [Globe and Mail, The (Toronto, Canada)]
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Scinai Immunotherapeutics (SCNI) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration [TheStreet.com]